"use strict";(self.webpackChunkBenStockTracker=self.webpackChunkBenStockTracker||[]).push([[5676],{5676:e=>{e.exports=JSON.parse('{"379a5117-44ff-3dd2-a2d2-f8e1385a8eef":{"uuid":"379a5117-44ff-3dd2-a2d2-f8e1385a8eef","title":"Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade","publisher":"News Direct","link":"https://finance.yahoo.com/news/gilead-statement-u-supreme-court-124538367.html","providerPublishTime":1656593138,"type":"STORY","relatedTickers":["GILD"]},"d47336fd-a875-372a-9334-65153d1c07f7":{"uuid":"d47336fd-a875-372a-9334-65153d1c07f7","title":"Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More","publisher":"Zacks","link":"https://finance.yahoo.com/news/biotech-stock-roundup-epzm-soars-155103141.html","providerPublishTime":1656517863,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/EejTULwUAYWc9k32qkXu0Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/obPyvmV.XkzkKLrDxW_bcA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/fPhGuVbDKu5w3I69zHQheA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/obPyvmV.XkzkKLrDxW_bcA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["EPZM","IPSEY","GILD","STRO"]},"4d11c019-67bf-350f-bdf3-462425002699":{"uuid":"4d11c019-67bf-350f-bdf3-462425002699","title":"Gilead\'s (GILD) Yescarta Gets EC Nod for Follicular Lymphoma","publisher":"Zacks","link":"https://finance.yahoo.com/news/gileads-gild-yescarta-gets-ec-142802825.html","providerPublishTime":1656512882,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/yQj7yY.zuCmH0g4AxJiWDg--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/4sNExajuO4U3uU3h3q2viA--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8727b578405dd8fbc1bc6364169b38d2","width":900,"height":469,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/hUbuInpukngibsDJT13G_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/4sNExajuO4U3uU3h3q2viA--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8727b578405dd8fbc1bc6364169b38d2","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["GILD","002722.SZ","NVS"]},"d3b3da96-fcef-33fe-88b6-eeaa5022adf5":{"uuid":"d3b3da96-fcef-33fe-88b6-eeaa5022adf5","title":"Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know","publisher":"Zacks","link":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-215009848.html","providerPublishTime":1656453009,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/dOFJjF.lFJbuBeMTQ.srQg--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a","width":900,"height":587,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/mmJVro2NZX9hs6RN4C.7CQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/aMCT_Lh5K9xNn9.QUdX03w--~B/aD01ODc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["GILD"]},"418fbcf9-80ec-32ab-89f0-543ff3cff9d7":{"uuid":"418fbcf9-80ec-32ab-89f0-543ff3cff9d7","title":"Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA","publisher":"Zacks","link":"https://finance.yahoo.com/news/gilead-gild-resubmits-nda-hiv-124912620.html","providerPublishTime":1656420552,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/rSifIemjGs.ArOt6hbnGLA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/RTGo4pt.TK_E0ckeUDNmXA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/IJCPk1k_kHOXYeWqzifXfg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/RTGo4pt.TK_E0ckeUDNmXA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f5ec5179112ff02b207f8fd4685c071","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["002722.SZ","GILD","GSK"]},"8554141a-ab64-3131-b26c-9c9dfdcc97f9":{"uuid":"8554141a-ab64-3131-b26c-9c9dfdcc97f9","title":"Gilead Leadership Organization of Black Employees (GLOBE) Raised the Juneteenth Flag","publisher":"News Direct","link":"https://finance.yahoo.com/news/gilead-leadership-organization-black-employees-124513911.html","providerPublishTime":1656420313,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/NEDCBUxWr47wvrVeCuIWvw--~B/aD00MzM7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/fsSAxga1AidOKArQZYlrFg--~B/aD00MzM7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/eed83f94a3dfb8c82c635f5dcfecb1fe","width":650,"height":433,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/JvZCXkrUaOLH4GOzU2xEzw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/fsSAxga1AidOKArQZYlrFg--~B/aD00MzM7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/eed83f94a3dfb8c82c635f5dcfecb1fe","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["GILD"]},"7535eddc-70fb-3af1-96ee-b7f5f01d5e67":{"uuid":"7535eddc-70fb-3af1-96ee-b7f5f01d5e67","title":"Kite\u2019s CAR T-cell Therapy Yescarta\xae Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma","publisher":"Business Wire","link":"https://finance.yahoo.com/news/kite-car-t-cell-therapy-100000100.html","providerPublishTime":1656410400,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/cpy9t8wv0tRVT.dgy7ZtkA--~B/aD0yMTA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/NUKsoe6cZfiGBd30iod2sw--~B/aD0yMTA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fd5170afddef06b741551b25b0cdf66c","width":480,"height":210,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/VRFzuE5mqbflBmaRQf_Qtw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/NUKsoe6cZfiGBd30iod2sw--~B/aD0yMTA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fd5170afddef06b741551b25b0cdf66c","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["GILD"]},"9b63072b-57b1-3857-8041-981a017a7d9b":{"uuid":"9b63072b-57b1-3857-8041-981a017a7d9b","title":"Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor","publisher":"Business Wire","link":"https://finance.yahoo.com/news/gilead-resubmits-drug-application-u-203000139.html","providerPublishTime":1656361800,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/3ZyG_k5FQiIwpcaaLIPwug--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/hEWZH0ox.AU2Wk3Tk063QA--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2c2d1f20f53da6697dde23c71248bd93","width":480,"height":160,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/qoxH4IfsaevcCJRFoFy1RA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/hEWZH0ox.AU2Wk3Tk063QA--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2c2d1f20f53da6697dde23c71248bd93","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["GILD"]}}')}}]);